Literature DB >> 24720730

The coexistence of an equal amount of Alzheimer's amyloid-β 40 and 42 forms structurally stable and toxic oligomers through a distinct pathway.

Yu-Jen Chang1, Yun-Ru Chen.   

Abstract

Fibrillar amyloid-β (Aβ) is the major constituent of senile plaques in the brain of patients with Alzheimer's disease (AD). Aβ is a short peptide generated from amyloid precursor protein with two main isoforms, Aβ40 and Aβ42, with the latter having two additional hydrophobic residues at the C-terminus. The two isoforms have distinct characteristics, in which Aβ42 plays a more pathogenic role. Some early-onset familial AD cases possess an elevated Aβ42/Aβ40 level, and biochemical studies show the two species interact with each other. Therefore, understanding structural conversion in the aggregation of mixed Aβ isoforms is essential for elucidating AD pathogenesis. Here, we systematically examined the differences between Aβ42, Aβ40 and various Aβ42/Aβ40 mixtures by monitoring the fibrillization kinetics, epitope changes, assembly, morphology and induced cytotoxicity. We found that the minor Aβ species in different mixing ratios modulated the major aggregation pathway. Size exclusion chromatography, circular dichroism spectroscopy and photo-crosslinking assay showed that soluble Aβ42 oligomers were stabilized after Aβ40 addition, and the equimolar Aβ42/Aβ40 mixture rapidly formed spherical oligomers. These oligomers were the most toxic among those examined as evidenced by neurite degeneration and neuronal toxicity. However, the oligomers were not responsible for intracellular calcium elevation. Overall, our results demonstrated that differently mixed Aβ species repartitioned oligomer intermediates on the major aggregation pathway. Furthermore, the equimolar mixture rapidly formed structurally stable and the most toxic oligomers. These results provided information on the potential pathological mechanisms underlying the elevated Aβ42/Aβ40 ratio in familial AD patients and in the local environment of sporadic AD brains.
© 2014 FEBS.

Entities:  

Keywords:  Alzheimer's disease; amyloid aggregation; amyloid-β isoforms; neurotoxicity; protein misfolding

Mesh:

Substances:

Year:  2014        PMID: 24720730     DOI: 10.1111/febs.12813

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  20 in total

1.  Aβ40 has a subtle effect on Aβ42 protofibril formation, but to a lesser degree than Aβ42 concentration, in Aβ42/Aβ40 mixtures.

Authors:  Shana E Terrill-Usery; Benjamin A Colvin; Richard E Davenport; Michael R Nichols
Journal:  Arch Biochem Biophys       Date:  2016-03-21       Impact factor: 4.013

2.  Intermittent hypoxia training blunts cerebrocortical presenilin 1 overexpression and amyloid-β accumulation in ethanol-withdrawn rats.

Authors:  Myoung-Gwi Ryou; Robert T Mallet; Daniel B Metzger; Marianna E Jung
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-05-10       Impact factor: 3.619

3.  C-Terminal Threonine Reduces Aβ43 Amyloidogenicity Compared with Aβ42.

Authors:  Saketh Chemuru; Ravindra Kodali; Ronald Wetzel
Journal:  J Mol Biol       Date:  2015-06-26       Impact factor: 5.469

Review 4.  Amyloid β structural polymorphism, associated toxicity and therapeutic strategies.

Authors:  Ofek Oren; Ran Taube; Niv Papo
Journal:  Cell Mol Life Sci       Date:  2021-10-13       Impact factor: 9.261

5.  Comparative pathobiology of β-amyloid and the unique susceptibility of humans to Alzheimer's disease.

Authors:  Rebecca F Rosen; Yasushi Tomidokoro; Aaron S Farberg; Jeromy Dooyema; Brian Ciliax; Todd M Preuss; Thomas A Neubert; Jorge A Ghiso; Harry LeVine; Lary C Walker
Journal:  Neurobiol Aging       Date:  2016-05-02       Impact factor: 4.673

6.  The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain.

Authors:  Silvia Fossati; Patrizia Giannoni; Maria E Solesio; Sarah L Cocklin; Erwin Cabrera; Jorge Ghiso; Agueda Rostagno
Journal:  Neurobiol Dis       Date:  2015-11-12       Impact factor: 5.996

Review 7.  Half a century of amyloids: past, present and future.

Authors:  Pu Chun Ke; Ruhong Zhou; Louise C Serpell; Roland Riek; Tuomas P J Knowles; Hilal A Lashuel; Ehud Gazit; Ian W Hamley; Thomas P Davis; Marcus Fändrich; Daniel Erik Otzen; Matthew R Chapman; Christopher M Dobson; David S Eisenberg; Raffaele Mezzenga
Journal:  Chem Soc Rev       Date:  2020-07-07       Impact factor: 54.564

Review 8.  Systematic review of the relationship between amyloid-β levels and measures of transgenic mouse cognitive deficit in Alzheimer's disease.

Authors:  Avery M Foley; Zeena M Ammar; Robert H Lee; Cassie S Mitchell
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

9.  A Robust and Efficient Production and Purification Procedure of Recombinant Alzheimers Disease Methionine-Modified Amyloid-β Peptides.

Authors:  Marie Hoarau; Yannick Malbert; Romain Irague; Christelle Hureau; Peter Faller; Emmanuel Gras; Isabelle André; Magali Remaud-Siméon
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

Review 10.  The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy.

Authors:  Urmi Sengupta; Ashley N Nilson; Rakez Kayed
Journal:  EBioMedicine       Date:  2016-04-05       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.